2014
Treatment of Hodgkin Lymphoma: A 50-Year Perspective
Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, DeVita VT. Treatment of Hodgkin Lymphoma: A 50-Year Perspective. Journal Of Clinical Oncology 2014, 32: 163-168. PMID: 24441526, DOI: 10.1200/jco.2013.53.1194.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBleomycinClinical Trials as TopicCyclophosphamideDacarbazineDisease-Free SurvivalDoxorubicinEtoposideEuropeHistory, 20th CenturyHodgkin DiseaseHumansMechlorethamineNeoplasm StagingPositron-Emission TomographyPrednisoneProcarbazineSurvival RateTomography, X-Ray ComputedTreatment OutcomeVinblastineVincristine
1997
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo D, Glatstein E, Duffey P, Young R, Ihde D, Bastian A, Wilson W, Wittes R, Jaffe E, Hubbard S, DeVita V. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Journal Of Clinical Oncology 1997, 15: 3338-46. PMID: 9363863, DOI: 10.1200/jco.1997.15.11.3338.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedPrednisoneProcarbazineProspective StudiesTreatment OutcomeVinblastineVincristineConceptsMantle field radiation therapyDisease-free survivalLarge mediastinal massMediastinal Hodgkin's diseaseHodgkin's diseaseABVD chemotherapyRadiation therapyOverall survivalMediastinal massMOPP/ABVDSecond solid tumorsTreatment-related pneumonitisComplete response rateAnn Arbor stageClinical prognostic factorsErythrocyte sedimentation rateTreatment of patientsAge 35 yearsLactate dehydrogenase levelsABVD therapyDacarbazine (ABVD) chemotherapyMedian followMOPP chemotherapySalvage therapyB symptoms
1994
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisRemission InductionSurvival RateVincristineConceptsAdvanced stage diseaseProMACE-MOPPProMACE-CytaBOMBurkitt's lymphomaLocalized diseaseComplete responseInvolved-field radiation therapyCombination chemotherapy programsOverall survival rateEfficacy of cyclophosphamideTreatment of patientsHigh-grade lymphomaMedian followComplete remissionIntercurrent illnessAdult patientsChemotherapy programCombination chemotherapyOverall survivalAggressive lymphomaRadiation therapyPatientsLymphomaSurvival rateDisease
1993
CHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma
Longo D, DeVita V, Young R. CHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma. New England Journal Of Medicine 1993, 329: 580-582. PMID: 7687747, DOI: 10.1056/nejm199308193290817.Peer-Reviewed Original Research
1991
Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo D, Duffey P, DeVita V, Wiernik P, Hubbard S, Phares J, Bastian A, Jaffe E, Young R. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. Journal Of Clinical Oncology 1991, 9: 1409-20. PMID: 1712836, DOI: 10.1200/jco.1991.9.8.1409.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinDose-Response Relationship, DrugDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansLeukemiaLomustineMaleMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission InductionStreptozocinSurvival RateVincristineConceptsAdvanced-stage Hodgkin's diseaseErythrocyte sedimentation rateDose intensityOverall survivalHodgkin's diseaseInitial erythrocyte sedimentation rateDisease-free survival ratesDisease-free survival curvesComplete response rateDisease-free survivalBetter overall survivalPoor prognostic factorSecondary acute leukemiaHigher platelet countsAssessable patientsPrognostic factorsPlatelet countAcute leukemiaTreatment outcomesMOPPPatientsResponse rateSurvival rateSurvival curvesDiseaseSuperiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal Of Clinical Oncology 1991, 9: 25-38. PMID: 1702144, DOI: 10.1200/jco.1991.9.1.25.Peer-Reviewed Original ResearchConceptsDaily days 1ProMACE-MOPPComplete remissionProMACE-CytaBOMDay 1Day 8Complete respondersSmall noncleaved-cell lymphomaComplete response rateCo-trimoxazole prophylaxisDouble-strength tabletProMACE-CytaBOM regimenTreatment-related causesTreatment-related mortalityPneumocystis carinii pneumoniaDiffuse aggressive lymphomasPeriod of treatmentDay 1 treatmentCombination chemotherapyAggressive lymphomaCarinii pneumoniaMalignant lymphomaEffective treatmentPatientsResponse rateLong-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas
Fisher R, Longo D, DeVita V, Hubbard S, Miller T, Young R. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Annals Of Oncology 1991, 2: 33-35. PMID: 1710487, DOI: 10.1093/annonc/2.suppl_1.33.Peer-Reviewed Original ResearchConceptsDisease-free survivalProMACE-MOPPCR rateComplete remissionProMACE-CytaBOMHodgkin's lymphomaLong-term disease-free survivalLong-term disease-free survivorsSurvival curvesStage IIDisease-free survival curvesFirst-generation regimensThird-generation regimensPhase II studyDisease-free survivorsOverall survival curvesSouthwest Oncology GroupCooperative group settingHigh-grade NHLNational Cancer InstituteSame time pointsVs 53Aggressive NHLII studyOncology Group
1986
Hematologic malignancies: non-Hodgkin's lymphomas.
DeVita V. Hematologic malignancies: non-Hodgkin's lymphomas. Hospital Practice 1986, 21: 103-18. PMID: 2427535.Peer-Reviewed Original Research
1985
ProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Fisher R, Young R, Longo D, DeVita V. ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Seminars In Oncology 1985, 12: 29-32. PMID: 2579441.Peer-Reviewed Original ResearchConceptsComplete remissionCombination chemotherapyAdvanced stageComplete response rateLong-term survivalMOPP combination chemotherapyC-MOPPComplete respondersNew regimenHodgkin's lymphomaBurkitt's lymphomaDiffuse lymphomaResponse rateFatal diseaseLymphomaPatientsDeath rateNCI studyHigh gradeRemissionChemotherapyDiseaseLarge cellsMyelosuppressionRegimen
1983
The cure of Hodgkin's disease with drugs.
DeVita V, Hubbard S, Moxley J. The cure of Hodgkin's disease with drugs. Advances In Internal Medicine 1983, 28: 277-302. PMID: 6188346.Peer-Reviewed Original Research
1979
Chemotherapy of Hodgkin's disease
Young R, DeVita V. Chemotherapy of Hodgkin's disease. Clinics In Haematology 1979, 8: 625-644. PMID: 91466, DOI: 10.1016/s0308-2261(79)80007-7.Peer-Reviewed Original ResearchConceptsAdvanced diseaseHodgkin's diseaseModality approachSuch long-term complicationsIIIB Hodgkin's diseaseInduction chemotherapy regimensPrimary induction failureShort initial remissionAdvanced Hodgkin's diseaseDisease-free survivalOverall survival ratePrognosis of patientsLong-term complicationsInduction failureAggressive therapyChemotherapy regimensComplete remissionInitial remissionLate complicationsSecond malignanciesCombination chemotherapySurvival benefitMOPP regimenActual survivalCombined modality
1977
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.
Anderson T, Bender R, Fisher R, DeVita V, Chabner B, Berard C, Norton L, Young R. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Journal Of The National Cancer Institute 1977, 61: 1057-66. PMID: 71205.Peer-Reviewed Original ResearchAdolescentAdultAgedBleomycinChildClinical Trials as TopicCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHumansLymphomaLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission, SpontaneousTime FactorsVincristinePrognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy
Fisher R, DeVita V, Johnson B, Simon R, Young R. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. The American Journal Of Medicine 1977, 63: 177-182. PMID: 70170, DOI: 10.1016/0002-9343(77)90230-3.Peer-Reviewed Original ResearchThe treatment of Hodgkin's disease
Young R, Anderson T, DeVita V. The treatment of Hodgkin's disease. Current Problems In Cancer 1977, 1: 1-29. PMID: 66119, DOI: 10.1016/s0147-0272(77)80009-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultBleomycinBone MarrowChildClinical Trials as TopicDrug Therapy, CombinationFemaleHodgkin DiseaseHumansLaparoscopyLaparotomyLiverLymph NodesMaleMechlorethamineNational Institutes of Health (U.S.)Neoplasms, Multiple PrimaryPrednisoneProcarbazineRadiotherapy, High-EnergySpleenSplenectomyUnited StatesVincristine
1976
Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Schein P, DeVita V, Hubbard S, Chabner B, Canellos G, Berard C, Young R. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Annals Of Internal Medicine 1976, 85: 417-22. PMID: 61732, DOI: 10.7326/0003-4819-85-4-417.Peer-Reviewed Original ResearchConceptsHistiocytic lymphomaAdvanced diffuse histiocytic lymphomaExtended disease-free survivalMixed histiocytic-lymphocytic lymphomaNew combination chemotherapy programHistiocytic-lymphocytic lymphomaPrednisone combination chemotherapyCompletion of therapyDiscontinuation of treatmentCombination chemotherapy programsDisease-free survivalDiffuse histiocytic lymphomaBone marrow functionMyelosuppressive phaseComplete remissionMedian durationChemotherapy programCombination chemotherapyComplete responseMarrow functionTumor recurrenceTreatment cyclesFatal diseasePatientsLymphoma
1975
High dose intravenous bleomycin in the treatment of advanced lymphomas
Hubbard S, Chabner B, Canellos G, Young R, DeVita V. High dose intravenous bleomycin in the treatment of advanced lymphomas. European Journal Of Cancer 1975, 11: 623-626. PMID: 56271, DOI: 10.1016/0014-2964(75)90096-1.Peer-Reviewed Original ResearchConceptsFull therapeutic doseAdvanced lymphomaIntravenous bleomycinAggressive therapyProgressive lymphomaIntermittent courseConventional dosesTherapeutic doseRapid administrationDose levelsResponse ratePatientsTotal dosesHigher total dose levelsLymphomaBleomycinDosesTotal dose levelsTreatmentTherapyAdministrationDoseReversible penile calcifications associated with bleomycin (NSC-125066)-induced pulmonary toxicity.
Ihde D, Gormley P, Francis R, DeVita V. Reversible penile calcifications associated with bleomycin (NSC-125066)-induced pulmonary toxicity. Cancer Chemotherapy Reports 1975, 59: 1039-41. PMID: 54214.Peer-Reviewed Original Research
1972
Clinical study with bleomycin: Tolerance to twice weekly dosage
Ohnuma T, Selawry O, Holland J, DeVita V, Shedd D, Hansen H, Muggia F. Clinical study with bleomycin: Tolerance to twice weekly dosage. Cancer 1972, 30: 914-922. PMID: 4116909, DOI: 10.1002/1097-0142(197210)30:4<914::aid-cncr2820300409>3.0.co;2-8.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaCell carcinomaDose levelsObjective tumor responseBody surface areaTherapeutic dose levelsOptimal dose levelNew antineoplastic agentsPulmonary infiltratesTransient hypertensionUrinary burningAbdominal distentionComplete remissionHematologic toxicityCutaneous toxicityWeekly dosesProlonged courseAdditional patientsPatient toleranceSkin toxicityMalignant neoplasmsTesticular carcinomaTumor responseTumor regressionWeekly dosageTreatment of the lymphomas.
DeVita V, Canellos G. Treatment of the lymphomas. Seminars In Hematology 1972, 9: 193-209. PMID: 4111886.Peer-Reviewed Original Research